The 10,000-scale 3D tumor database will establish a win-win "ladder plan"

[ China Pharmaceutical Network Technology News ] On March 1, Zhan Qimin, academician of the Chinese Academy of Engineering and head of the National Precision Medical Strategy Expert Group, and Zhou Caicun, director of the Cancer Research Institute of Tongji University School of Medicine, and hundreds of scientific experts, industry leaders, industry veterans, etc. Participated in the first "tumor genome and precision immunotherapy" summit forum held in Shanghai. At the forum, they jointly explored new paradigms for cancer treatment; explored new ways to promote the combination of immunotherapeutic technology and genomics technology; explore new ways to achieve true tumor-precise immunotherapy.

It is worth mentioning that the first genomic cooperation plan “Training Plan” launched in China for tumor immunotherapy was also officially released at this forum.

Immunotherapy is developing rapidly, but "anti-cancer landing on the moon" still needs "ladder"

In recent years, immunotherapy represented by PD-1, CAR-T, etc. has shown remarkable therapeutic effects on many cancerous species, and is internationally known as the most likely "terminator" of cancer. The great success of immunotherapy is inseparable from the deep understanding of the tumor microenvironment and its interaction with the immune system, as well as the rapid development of genomic research and bioinformatics analysis. However, immunotherapy is still not perfect, and the development of immunotherapy requires multidisciplinary and cross-disciplinary integration. Therefore, combining immunotherapy technology with genomics technology to achieve true tumor accurate immunotherapy has become the forefront of current international research on tumor immunotherapy.

At the beginning of 2016, American folk scientists and the government successively proposed the Cancer Moon 2020 and CancerMoonShot, hoping to accelerate cooperation in various disciplines and accelerate the capture of cancer.

Prior to the release of the "Ladder Plan", various expert teams in China's academia and industry have begun to use genetic sequencing and big data research to accelerate the exploration and accumulation of cancer immunotherapy. Different teams from the fields of gene sequencing, big data analysis, and cancer immunotherapy have achieved certain research results for the same goal, independent research and development, or mutual research and development. However, at present, although the research has been in full swing, there are also problems of scattered power and unstandardized standards. In particular, the field needs multidisciplinary and multi-technology integration. In the early stage, it is necessary to concentrate and standardize.

It is understood that the "China Anti-Cancer Moon and Ladder Plan" was initiated by Yuce Bio, a leading technology company focusing on tumor genome and immunotherapy, and was chaired by the Chinese Academy of Engineering academician Zhan Qimin as the chairman of the expert advisory committee. The genomic cooperation program initiated by immunotherapy aims to use genetic testing and big data analysis to mobilize the immune system to fight cancer, accelerate cancer treatment research, achieve a lunar feat to cure cancer, and build a cooperative, mutually beneficial and win-win anti-cancer. Ladder."

Establish "two libraries and one standard", China's ladder to help immune treatment leapfrog breakthrough

Gao Zhibo, founder and CEO of Yucei, said that by 2020, the “ladder plan” will achieve the strategic goal of “two libraries and one standard”, and then provide adjuvant treatment decisions for scientists and doctors in clinical cancer treatment, and develop for pharmaceutical companies. The drug provides a reliable target selection, accelerates the latest cancer immunotherapy, and achieves a leap-forward breakthrough in cancer prevention and treatment.

The so-called "two libraries and one standard", the first library refers to the first 10,000-level 3D tumor database in China. Based on database mining and analysis, it will be able to treat immunological checkpoint inhibitors represented by PD-1 drugs. Establish methods and criteria for predicting the efficacy, establish a method and standard for the detection of tumor-specific antigens (neoantigen) for cellular immunotherapy, and lay the foundation for the development and development of immunotherapy technology. In turn, some patients are guided to conduct precise and personalized immunotherapy, improve clinical treatment results, and accumulate experience for precise immunotherapy.

The second library refers to the first comprehensive, updated and timely knowledge database of tumor immunity in China, including the latest technological progress, clinical trials, clinical cases, industry trends and other information related to tumor immunotherapy, which can provide the industry with the latest technological progress. And industry trends to promote technological advancement and common development in the industry, non-professionals can obtain the latest clinical and technological developments, and promote science education in immunotherapy and genetic testing technology.

“One standard” refers to the establishment of the first open source and open tumor immunotherapy gene detection evaluation system and standards in China, focusing on industry strengths and jointly solving related technical difficulties and pain points, thus guiding the various institutions in the industry to effectively carry out the standard testing process.

Gao Zhibo also revealed that the “ladder plan” will actively cooperate with oncology research institutions and experts, hospital institutions and clinicians, and pharmaceutical companies. At present, dozens of institutions including Huada Gene, Xiangxue Pharmaceutical, Judao Technology, Tongshu Bio, Aiji Taikang, and Yuanzheng Cell have signed on-site to support the implementation of the “Ladder Plan”.

"Discovering and validating tumor nascent antigens, providing adjuvant treatment decisions; simultaneously discovering and developing new potential drug targets and predicting drug treatment outcomes is the goal of the 'ladder plan'." Gao Zhibo said.

In addition, in this forum, Yuce Bio has officially released the first comprehensive genetic testing product YeceOne?Plus in China to guide tumor immunotherapy, targeted therapy and chemotherapy, as well as the first domestic evaluation of immune checkpoint suppression based on multiple indicators. The gene detection product of the agent, YuceOne? ICIs, brings more hope to domestic cancer patients.

Gao Zhibo said that the "Tian Ladder Plan" will also be based on the new YuceOne? product line released by Yuce Bio, which will help and build a cooperative, mutually beneficial and win-win anti-cancer "ladder".